Belzutifan: First Approval

Ways into Understanding HIF Inhibition

(2021) Tina Schönberger et al.   Cancers

Phase 2 study of the oral hypoxia-inducible factor 2α (HIF-2α) inhibitor MK-6482 in combination with cabozantinib in patients with advanced clear cell renal cell carcinoma (ccRCC).

(2021) Toni K. Choueiri et al.   JOURNAL OF CLINICAL ONCOLOGY

Inhibition of hypoxia-inducible factor-2α in renal cell carcinoma with belzutifan: a phase 1 trial and biomarker analysis

(2021) Toni K. Choueiri et al.   NATURE MEDICINE

Phase 2 study of belzutifan (MK-6482), an oral hypoxia-inducible factor 2α (HIF-2α) inhibitor, for Von Hippel-Lindau (VHL) disease-associated clear cell renal cell carcinoma (ccRCC).

(2021) Ramaprasad Srinivasan et al.   JOURNAL OF CLINICAL ONCOLOGY

The Many Facets of Erythropoietin Physiologic and Metabolic Response

(2020) Sukanya Suresh et al.   Frontiers in Physiology

From oxygen sensing to angiogenesis: Targeting the hypoxia signaling pathway in metastatic kidney cancer

(2020) Clement Chung   AMERICAN JOURNAL OF HEALTH-SYSTEM PHARMACY

Therapeutic inhibition of HIF2α reverses polycythemia and pulmonary hypertension in murine models of two human diseases

(2020) Manik C Ghosh et al.   BLOOD

Towards individualized therapy for metastatic renal cell carcinoma

(2019) Ritesh R. Kotecha et al.   Nature Reviews Clinical Oncology

3-[(1S,2S,3R)-2,3-Difluoro-1-hydroxy-7-methylsulfonylindan-4-yl]oxy-5-fluorobenzonitrile (PT2977), a Hypoxia-Inducible Factor 2α (HIF-2α) Inhibitor for the Treatment of Clear Cell Renal Cell Carcinoma

(2019) Rui Xu et al.   JOURNAL OF MEDICINAL CHEMISTRY

Allosteric inhibition of HIF-2α as a novel therapy for clear cell renal cell carcinoma

(2019) Yancheng Yu et al.   DRUG DISCOVERY TODAY

von Hippel–Lindau disease: A clinical and scientific review

(2011) Eamonn R Maher et al.   EUROPEAN JOURNAL OF HUMAN GENETICS

Improved Identification of von Hippel-Lindau Gene Alterations in Clear Cell Renal Tumors

(2008) M. L. Nickerson et al.   CLINICAL CANCER RESEARCH